spacer
home > ebr > autumn 2009 > designer therapeutic proteins
PUBLICATIONS
European Biopharmaceutical Review

Designer Therapeutic Proteins

 

Botulinum neurotoxin has achieved celebrity status through its use in cosmetic treatment. The most lethal toxin known in nature, it is also a notorious cause of the deadly food poisoning, botulism. Lay patients are less aware, however, that its ability to relax and paralyse muscles has many therapeutic applications.

It is not a perfect therapy, despite being used to treat inappropriate or excessive contractions of muscles throughout the body. Botulinum neurotoxin remains a highly toxic substance and a recognised bioterrorism threat, and it is only safe when used in low nanogram quantities. Since the toxin evolved to target nerve cells specifically, its effects are limited to conditions involving peripheral nerve transmission, and muscle relaxation in particular.

Both the toxic and therapeutic effects of botulinum neurotoxin arise from the same property: the ability to inhibit neurotransmitter release from nerve cells. Imagine if botulinum neurotoxinís ability to target and inhibit nerve cell secretions could be widened to other cell types, while rendering it non-lethal.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Keith Foster is Founder and Head of Technology Development at Syntaxin Ltd. An internationally recognised expert on botulinum neurotoxins, he led the team at the UK Health Protection Agency that developed the proprietary technology that is the basis of Syntaxin, and co-led the spin-out of Syntaxin from the HPA in November 2005. He is an inventor on 16 international patent families with 29 granted patents worldwide, including the core patents underpinning Syntaxinís neurotoxin technology, and has published over 40 scientific papers. Keith has over 25 yearsí management experience in pharmaceutical R&D, including positions with SmithKline Beecham and Ipsen. He has an MA in Natural Science from the University of Cambridge and a PhD from the University of London.
spacer
Keith Foster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Julia Forjanic Klapproth, Senior Partner at Trilogy Writing & Consulting receives the Harold Swanberg Distinguished Service Award 2022

Trilogy Writing & Consulting, a company specialised in regulatory writing, announced that one of its Senior Partners, Julia Forjanic Klapproth, was honored with the Harold Swanberg Distinguished Service Award during the American Medical Writers Association (AMWA) conference that took place in Denver, CO, in the beginning of November 2022.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement